Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
The purpose of the study is to assess the safety, tolerability, pharmacokinetics and immunoregulatory activity of urelumab (BMS-663513) in cancer subjects with advanced and/or metastatic tumors and relapsed/refractory B-Cell Non-Hodgkin's Lymphoma
Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma
DRUG: Urelumab (BMS-663513)
Safety assessments will be based on medical review of adverse event reports and the results of vital sign measurements, physical examinations, and clinical laboratory tests, The incidence of adverse events will be tabulated and reviewed for potential significance and clinical Importance., Every 3 weeks from Baseline (Day 1) for up to 2 years|Dose-limiting toxicity and maximum tolerated dose of Urelumab (BMS-663513) as determined by the incidence of dose-limiting toxicities, Every 3 weeks from Baseline (Day 1) for up to 9 weeks of therapy
Maximum observed serum concentrations (Cmax) of Urelumab (BMS-663513), Cycle 1 Day 1|Minimum observed serum concentrations (Cmin) of Urelumab (BMS-663513), Cycle 2 Day 1, Cycle 3 Day 1, every 12 weeks thereafter up to 2 years|Time of maximum observed serum concentration (Tmax) of Urelumab (BMS-663513), Cycle 1 Day 1|Area under the concentration-time curve in 1 dosing interval [AUC(TAU)] of Urelumab (BMS-663513), Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years|Plasma half-life (T-HALF) of Urelumab (BMS-663513), Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years|Total body clearance (CLT) of Urelumab (BMS-663513), Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years|Volume of distribution at steady-state (Vss) of Urelumab (BMS-663513), Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years|Human Anti-human Antibodies, Immunogenicity of Urelumab (BMS-663513), as determined by blood sample measurements of human antihuman antibodies (HAHA), Cycle 1 Day 1 - Day 4, Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 3 Day 1 and every 12 weeks thereafter up to 2 years|Tumor response and progression as determined by proportion of patients with best overall response (BOR), progression-free survival (PFS), objective response rate (ORR), time to response, and duration of response, 9 weeks from Baseline (Day 1) and every 9 weeks until disease progression, death or last tumor assessment (Approximately up to 2 years)
The purpose of the study is to assess the safety, tolerability, pharmacokinetics and immunoregulatory activity of urelumab (BMS-663513) in cancer subjects with advanced and/or metastatic tumors and relapsed/refractory B-Cell Non-Hodgkin's Lymphoma